US Pharma MarketingRatio Therapeutics secures $70m Series C funding for cancer radiotherapy
Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Ratio Therapeutics, a US-based developer of radiopharmaceuticals for cancer treatment, has closed a $70m Series C financing round.
Source: Pharmaceutical Technology